Literature DB >> 27927600

Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Elaine Ku1, Michael S Lipkowitz2, Lawrence J Appel3, Afshin Parsa4, Jennifer Gassman5, David V Glidden6, Miroslaw Smogorzewski7, Chi-Yuan Hsu8.   

Abstract

Although APOL1 high-risk genotype partially accounts for the increased susceptibility of blacks to chronic kidney disease (CKD), whether APOL1 associates differentially with mortality risk remains controversial. Here we evaluate the association between APOL1 genotype and risk of death and determine whether APOL1 status modifies the association between strict versus usual blood pressure control and mortality risk. We performed a retrospective analysis of the African American Study of Kidney Disease and Hypertension trial that randomized black participants with CKD to strict versus usual blood pressure control from 1995 to 2001. This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial. During a median follow-up of 14.5 years, risk of death did not differ between individuals with high- versus low-risk APOL1 genotypes (unadjusted hazard ratio 1.00 [95% confidence interval 0.76-1.33]). However, a significant interaction was detected between the APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, the risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, the risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]). Thus, strict blood pressure control during CKD associates with a lower risk of death in blacks with the high-risk CKD APOL1 genotype. Knowledge of APOL1 status could inform selection of blood pressure treatment targets in black CKD patients.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOL1 genotype; CKD; mortality

Mesh:

Substances:

Year:  2016        PMID: 27927600      PMCID: PMC5237400          DOI: 10.1016/j.kint.2016.09.033

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  45 in total

1.  Identifying a national death index match.

Authors:  Gerda G Fillenbaum; Bruce M Burchett; Dan G Blazer
Journal:  Am J Epidemiol       Date:  2009-06-30       Impact factor: 4.897

2.  Apolipoprotein L1-associated nephropathy and the future of renal diagnostics.

Authors:  Christopher P Larsen; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2015-01-08       Impact factor: 10.121

3.  Regional variation in health care intensity and treatment practices for end-stage renal disease in older adults.

Authors:  Ann M O'Hare; Rudolph A Rodriguez; Susan M Hailpern; Eric B Larson; Manjula Kurella Tamura
Journal:  JAMA       Date:  2010-07-14       Impact factor: 56.272

4.  End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Authors:  Barry I Freedman; Carl D Langefeld; Kelly K Andringa; Jennifer A Croker; Adrienne H Williams; Neva E Garner; Daniel J Birmingham; Lee A Hebert; Pamela J Hicks; Mark S Segal; Jeffrey C Edberg; Elizabeth E Brown; Graciela S Alarcón; Karen H Costenbader; Mary E Comeau; Lindsey A Criswell; John B Harley; Judith A James; Diane L Kamen; S Sam Lim; Joan T Merrill; Kathy L Sivils; Timothy B Niewold; Neha M Patel; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Jane E Salmon; Betty P Tsao; Keisha L Gibson; Joyce R Byers; Anna K Vinnikova; Janice P Lea; Bruce A Julian; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

5.  Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Authors:  Teresa K Chen; Michael J Choi; W H Linda Kao; Brad C Astor; Julia J Scialla; Lawrence J Appel; Liang Li; Michael S Lipkowitz; Myles Wolf; Rulan S Parekh; Cheryl A Winkler; Michelle M Estrella; Deidra C Crews
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-01       Impact factor: 8.237

6.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

7.  The conundrum of increased burden of end-stage renal disease in Asians.

Authors:  Yoshio N Hall; Chi-yuan Hsu; Carlos Iribarren; Jeanne Darbinian; Charles E McCulloch; Alan S Go
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

8.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

9.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

10.  Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.

Authors:  Elaine Ku; David V Glidden; Kirsten L Johansen; Mark Sarnak; Hocine Tighiouart; Barbara Grimes; Chi-Yuan Hsu
Journal:  Kidney Int       Date:  2014-12-10       Impact factor: 10.612

View more
  14 in total

1.  You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease.

Authors:  Ebele M Umeukeje; Bessie A Young; Stephanie M Fullerton; Kerri Cavanaugh; Delia Owens; James G Wilson; Wylie Burke; Erika Blacksher
Journal:  J Am Soc Nephrol       Date:  2019-03-11       Impact factor: 10.121

2.  Diversity and inclusion in genomic research: why the uneven progress?

Authors:  Amy R Bentley; Shawneequa Callier; Charles N Rotimi
Journal:  J Community Genet       Date:  2017-07-18

3.  Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.

Authors:  Bessie A Young; Erika Blacksher; Kerri L Cavanaugh; Barry I Freedman; Stephanie M Fullerton; Jeffrey B Kopp; Ebele M Umeukeje; Kathleen M West; James G Wilson; Wylie Burke
Journal:  Am J Nephrol       Date:  2019-09-03       Impact factor: 3.754

4.  Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.

Authors:  Elaine Ku; Joachim H Ix; Kenneth Jamerson; Navdeep Tangri; Feng Lin; Jennifer Gassman; Miroslaw Smogorzewski; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2018-07-13       Impact factor: 10.121

5.  Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?

Authors:  Jenny Wei; Kirsten L Johansen; Charles E McCulloch; Michael Lipkowitz; Matthew Weir; Feng Lin; Vito M Campese; Miroslaw Smogorzewski; Elaine Ku
Journal:  Am J Kidney Dis       Date:  2019-12-16       Impact factor: 8.860

6.  Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.

Authors:  Barry I Freedman; Wylie Burke; Jasmin Divers; Lucy Eberhard; Crystal A Gadegbeku; Rasheed Gbadegesin; Michael E Hall; Tiffany Jones-Smith; Richard Knight; Jeffrey B Kopp; Csaba P Kovesdy; Keith C Norris; Opeyemi A Olabisi; Glenda V Roberts; John R Sedor; Erika Blacksher
Journal:  J Am Soc Nephrol       Date:  2021-04-14       Impact factor: 14.978

7.  APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial.

Authors:  Barry I Freedman; Michael V Rocco; Jeffrey T Bates; Michel Chonchol; Amret T Hawfield; James P Lash; Vasilios Papademetriou; John R Sedor; Karen Servilla; Paul L Kimmel; Barry M Wall; Nicholas M Pajewski
Journal:  Kidney Int Rep       Date:  2017-03-31

Review 8.  At the Research-Clinical Interface: Returning Individual Genetic Results to Research Participants.

Authors:  Kathleen M West; Erika Blacksher; Kerri L Cavanaugh; Stephanie M Fullerton; Ebele M Umeukeje; Bessie A Young; Wylie Burke
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-10       Impact factor: 8.237

9.  Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management.

Authors:  Thomas M Schneider; Michael T Eadon; Rhonda M Cooper-DeHoff; Kerri L Cavanaugh; Khoa A Nguyen; Meghan J Arwood; Emma M Tillman; Victoria M Pratt; Paul R Dexter; Allison B McCoy; Lori A Orlando; Stuart A Scott; Girish N Nadkarni; Carol R Horowitz; Joseph L Kannry
Journal:  J Pers Med       Date:  2021-05-27

10.  Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality.

Authors:  Elaine Ku; Joel D Kopple; Kirsten L Johansen; Charles E McCulloch; Alan S Go; Dawei Xie; Feng Lin; L Lee Hamm; Jiang He; John W Kusek; Sankar D Navaneethan; Ana C Ricardo; Hernan Rincon-Choles; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 11.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.